Digilab BioVisioN GmbH closes cooperation agreement with Boehringer Ingelheim

06-Apr-2006

Digilab BioVisioN GmbH announced closing of a cooperation contract with Boehringer Ingelheim Pharma GmbH & Co. KG. This is the first collaboration contract of the company that takes over commercial activities from BioVisioN AG within a reorganization process.

Within the project Digilab BioVisioN will analyze the quantitative peptide content of biological samples for the German pharmaceutical company. Using the patent-protected Peptidomics®-Technologies of Digilab BioVisioN, differences in peptide patterns are sought in order to identify new biomarkers. Further details of the project were not released.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances